Brought to you by 
RDO brings in $11.5mm for AEterna Zentaris
17 Jun 2010
Executive Summary
AEterna Zentaris Inc. (mainly develops therapies for cancer and endocrinology disorders) netted $11.5mm through the registered direct offering of 8.8mm common shares at $1.37 each (a 7% discount) to institutional investors. The company also issued five-year warrants to purchase 4.4mm common shares exercisable at the same price. Rodman & Renshaw was the placement agent.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
RDO brings in $11.5mm for AEterna Zentaris
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice